When was Quantum Biopharma founded?

Quantum Biopharma was founded in 2020 and raised its 1st funding round 4 years after it was founded.

Where is Quantum Biopharma located?

Quantum Biopharma is headquartered in Toronto, Canada.

Who is the current CEO of Quantum Biopharma?

Zeeshan Saeed of Quantum Biopharma. They have also founded 2 companies.

How many employees does Quantum Biopharma have?

As of May 27, 2025, the latest employee count at Quantum Biopharma is 49.

Is Quantum Biopharma a funded company?

Quantum Biopharma is a funded company, having raised an undisclosed amount across 2 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on Dec 13, 2024.

When was the latest funding round of Quantum Biopharma?

Quantum Biopharma's latest funding was a $***** Post IPO round on Nov 12, 2025, with participation from 0 investor.

Where does Quantum Biopharma rank among its competitors?

Quantum Biopharma ranks 71st amongst 457 active competitors, of which 159 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Alchemab, which secured $34M in Jul, 2026.

Who are the top competitors of Quantum Biopharma?

Quantum Biopharma's top competitors include Denali Therapeutics, Regenxbio and AviadoBio. Among them, Alchemab secured the most recent funding round in July, 2026.

Quantum Biopharma - 2026 Company Profile, Team, Funding & Competitors

Company Details

Developer of therapies for neurodegenerative and neuropsychiatric diseases. It offers myelin repairing compounds which include Lucid-MS a patented neuroprotective compound that prevent and reverse myelin degradation, a cause for Multiple Sclerosis, as well as other neurodegenerative diseases and conditions.

Website: quantumbiopharma.com
Social
Email ID: *****@quantumbiopharma.com

Key Metrics

Founded Year

2020

Location

Toronto, Canada

Stage

Public

Latest Funding Round

Post IPO, Nov 12, 2025, $*****

Ranked

71^st among 457 active competitors

Employee Count

49 as on May 27, 2025

Similar Companies

Denali Therapeutics & 567 more

Exit Details

Public

View Quantum Biopharma's full profile

Quantum Biopharma got listed on Jun 08, 2018.

Click here to take a look at Quantum Biopharma's IPO in detail

Quantum Biopharma has raised funding over 2 rounds. Its first funding round was on Dec 13, 2024.

Here is the list of recent funding rounds of Quantum Biopharma:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 12, 2025	3754429	Post IPO	8954530	6576157	5171600	9368067
Dec 13, 2024	8402258	Post IPO	5595974	7302085	7522693	6529616

Access funding benchmarks and valuations. Sign up today!

View details of Quantum Biopharma's funding rounds and investors

The founders of Quantum Biopharma are Zeeshan Saeed and Anthony Durkacz. Zeeshan Saeed is the CEO of Quantum Biopharma.

Here are the details of Quantum Biopharma's key team members:

Zeeshan Saeed: Co-Founder & CEO of Quantum Biopharma and founder of 2 other companies, Ronday and FSD Pharma.
Contact Info: 1 email address
Anthony Durkacz: Co-Founder of Quantum Biopharma and founder of 2 other companies, Ronday and FSD Pharma.

View details of Quantum Biopharma's Founder profiles and Board Members

Quantum Biopharma's employee count trend

Quantum Biopharma has 49 employees as of May 25. Here is Quantum Biopharma's employee count trend over the years:

Employee count trend for Quantum Biopharma

Uncover Quantum Biopharma's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Quantum Biopharma include Denali Therapeutics, Regenxbio and AviadoBio. Here is the list of Top 10 competitors of Quantum Biopharma, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Denali Therapeutics 2015, San Francisco (United States), Public	Developer of therapies to treat neurodegenerative diseases	$347M	Foresite Capital, Baillie Gifford & 10 others	74/100
2nd	Regenxbio 2008, Rockville (United States), Public	Developer of AAV Gene Therapy for rare genetic diseases	$108M	Brookside Capital, Venrock & 15 others	68/100
3rd	AviadoBio 2019, London (United Kingdom), Series A	Developer of gene therapies for neurodegenerative disorders	$80M	Monograph, New Enterprise Associates & 9 others	67/100
4th	Alchemab 2019, London (United Kingdom), Series A	Developer of antibody therapeutics for treating oncology and neurodegenerative conditions	$149M	RA Capital Management, SV Health Investors ... & 14 others	66/100
5th	Mission Therapeutics 2011, Cambridge (United Kingdom), Series D	Developer of small molecule inhibitors targeting specific disease associated enzymes	$192M	Sofinnova Partners, Pfizer Venture Investments ... & 46 others	64/100
6th	US World Meds 2001, Louisville (United States), Series B	Developer of therapeutics for the treatment of multiple diseases	$149M	Athyrium Capital Management, CRG & 6 others	64/100
7th	Blue Rock Therapeutics 2016, Boston (United States), Acquired	Stem cell therapies for cardiovascular and neurological diseases	$225M	Versant Ventures, Leaps by Bayer & 1 others	64/100
8th	Annexon 2011, San Francisco (United States), Public	Developer of antibodies to treat complement-mediated neurodegenerative diseases	$256M	Redmile Group, Bain Capital & 17 others	64/100
9th	D&D Pharmatech 2014, Seongnam-si (South Korea), Public	Developer of GLP-1-based therapeutics for metabolic disease treatment	$205M	Praxis Capital, Smile Gate Investment & 10 others	63/100
10th	Amylyx Pharmaceuticals 2013, Cambridge (United States), Public	Developer of small-molecule therapeutics for neurodegenerative diseases	$172M	Morningside, Viking Global Investors & 16 others	63/100
71st	Quantum Biopharma 2020, Toronto (Canada), Public	Developer of therapies for neurodegenerative and neuropsychiatric diseases	-	-	50/100